Medial vs Lateral Approach for Total Knee Replacement on Valgus Knee: a Randomized Clinical Trial (ValgusKnee)
Medial vs Lateral Approach for Total Knee Replacement on Valgus Knee: Prospective and Randomized Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Gustavo C Campos, MD
- Phone Number: +551983318000
- Email: gustavoccampos@terra.com.br
Study Locations
-
-
SP
-
Campinas, SP, Brazil, 13083-888
- Recruiting
- Hospital de Clinicas da UNICAMP
-
Contact:
- Alessandro R Zorzi, MsC
- Phone Number: +5519992809303
- Email: alessandrozorzi@uol.com.br
-
Principal Investigator:
- Alessandro R Zorzi, MsC
-
Sub-Investigator:
- Gustavo C Campos, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Severe osteoarthritis (Kellgren & Lawrence grade 4)
- Valgus deformity of the knee
- Read and sign the informed consent form
Exclusion Criteria:
- Severe pain in other joint (VAS>6)
- Comorbidities or any condition that contraindicate the procedure
- Previous arthroplasty on the index knee
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Medial approach
Medial parapatellar approach (classic approach)
|
Total knee replacement performed through a longitudinal incision medial to the patella
Other Names:
|
|
Experimental: Keblish approach
Lateral parapatellar approach (Keblish approach)
|
Total knee replacement performed through a longitudinal incision lateral to the patella
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Knee Score
Time Frame: 1 year
|
Evaluation of patient's pain and function using the Knee Society questionnaire
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
WOMAC
Time Frame: 2 years
|
Evaluation of patient's symptoms using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)
|
2 years
|
|
VAS
Time Frame: 2 years
|
Evaluation of patient's symptoms using the VAS (Visual Analogic Scale of pain)
|
2 years
|
|
Knee alignment
Time Frame: 6 months
|
Radiographic analysis of the knee alignment
|
6 months
|
|
Hemoglobin
Time Frame: 3 days
|
Analysis of patient's hemoglobin to estimate blood loss
|
3 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Alessandro R Zorzi, MsC, University of Campinas
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- VALGUSKNEE
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.